News

Living with Chronic Pain

August 12, 2021
|
The EO Team

Living with Chronic Pain

Chronic pain is prevalent. A 2016 report estimates that over 20% of adults in the United States have experienced some form of chronic pain. Of those 50 million Americans, 8% suffer from some form of high impact chronic pain; pain that has lasted over three months and prohibits them from performing important activities in their daily lives.

Chronic pain is persistent. It can present as headaches, arthritis, or irritable bowel syndrome, to name just a few. Regardless of how it manifests; when it shows up, chronic pain sticks around. Chronic pain occurs daily and can last for weeks, months, or years.


Chronic pain is expensive. In more ways than one. On the national level, it costs Americans an estimated $560 billion in medical expenses, disability programs, and productivity. On the personal level, it can cost sufferers the ability to perform many activities of daily life. With chronic pain, it is difficult to socialize, focus, sleep, and generally take care of yourself. As stress from work and life heightens, chronic pain becomes more costly.

<-  Back to blog
More
News
News

EO Care, Inc. Statement on Proposed Federal Register Change

As the leader in cannabinoid based symptom management for older adults, we applaud the Centers for Medicare & Medicaid Services (CMS) proposal to expand coverage for federally legal, hemp-derived cannabinoid-based products. At EO, we are uniquely positioned to meet the need of this new, covered cannabinoid care market.

Read More
Read More
News

EO Data & Methodology: November 2025 Update

At EO, we systematically track how patients feel and function after starting guided cannabis care. The data below come from real people using cannabis to manage symptoms such as pain, sleep disturbance, anxiety, and nausea/vomiting, under the guidance of our clinical protocols.

Read More
Read More
News

EO Care Releases Latest Cannabinoid-Based Symptom Management Efficacy Data

Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.

Read More
Read More